As a next step in the selection process, an expert jury consisting of leading entrepreneurial personalities and biotechnology ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Evopoint Biosciences (Evopoint Biosciences Co., Ltd.) today announced they have entered into an exclusive license ...

The selected finalists have demonstrated entrepreneurial execution and translational potential for a range of scientific approaches The winner(s) will be officially announced on July 3, 2025, and will ...

Comprehensive preclinical results will be presented for Debio 1562M, a next-generation Antibody-Drug Conjugate (ADC) targeting the cell surface glycoprotein CD37 soon to undergo first-in-human ...

an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds coupled to an antibody via a linker molecule.

French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung cancer (NSCLC).

Abstract: This paper presents a low-power 12-bit 100-MS/s asynchronous successive approximation register analog-to-digital converter (SAR ADC). Several techniques are developed to enhance the ADC ...

Abstract: This paper presents a 9-bit 1.8 GS/s pipelined analog-to-digital converter (ADC) using open-loop amplifiers. In this ADC, open-loop amplifiers are used as residue amplifiers to increase the ...

6b01753. PXRD of the catalysts before and after reaction, nitrogen sorption and pore size distribution measurements, 1 H NMR of digested MOFs, synthetic routes to the bipyridyl linkers, and supporting ...